Tekmeriα
§ I

Beyond Clinical Success, Commercial Certainty

Tekmeria is a predictive intelligence platform that translates complex payer logic into quantitative insights to maximize commercial success and ensure that life-changing medicines reach the patients they were built for.

§ II · The Scale of Intelligence

Evidence-Based. Data-Backed. Battle-Tested.

Our models are not hallucinating; they are referencing a massive, structured dataset of historical reality.

i.

20+

Years of Clinical Guidelines

tracked for semantic evolution

Temporal depth

ii.

15,000+

HTA Decisions

(G-BA, HAS, NICE) ingested and labeled

Regulatory breadth

iii.

120,000+

Clinical Trials

analyzed for comparator and endpoint trends

Clinical corpus

iv.

2,500+

Proprietary Features

engineered per therapeutic indication

Engineering depth

v.

94%

Prediction Accuracy

verified against historical payer decisions

Validation result

Sources: G-BAHASNICEICERPBACCADTHTLVAIFA

§ III · Expertise

Our Solutions

Unifying clinical strategy and market reality to maximize asset value.

i.

Clinical Development

Embed commercial viability into trial design. Move beyond regulatory compliance by integrating payer logic into your protocols, ensuring your clinical evidence secures future reimbursement.

Fig. ii.

Dual-gate acceptance lens: endpoint candidates positioned across regulator and payer fields; PFS sits in the agreement region. DOR DFS OS ORR PFS 0.94 ϱ × π n = 5
Explore Protocol Engineering

ii.

Market Access

Maximize revenue potential with predictive certainty. Replace guesswork with quantitative foresight to de-risk HTA submissions, accelerate time-to-market, and secure the optimal price for your therapy.

Fig. iii.

Multi-jurisdiction price forecast: five EU5 countries with predicted price corridors threaded by a weighted-average meridian. 40 60 80 100 120 € × 10³ DE G-BA FR HAS UK NICE IT AIFA ES AEMPS μ = 72.4 τ = 0.94
Advance Market Strategy
§ IV

Our Platform

A proprietary System of Intelligence. Powered by an orchestrated hive of specialized predictive Micro-Agents, we translate qualitative regulatory text into computable vectors—turning "regulatory intuition" into math. By simulating the distinct decision logic of national HTA bodies, our system transforms complex data into a single, commercially actionable strategy.

Tekmeria platform architecture: inputs through specialized agents and ensemble layer to forecasted outcome. i. ii. iii. iv. v. HTA DECISIONS Historical Outcomes CLINICAL GUIDELINES Regulatory Standards TRIAL DATA Evidence & Endpoints Endpoint Vector Pop. Alignment Stat. Robustness ENDPOINT ACCEPTANCE COMPARATOR ALIGNMENT SUBGROUP RELEVANCE ENSEMBLE LAYER FORECASTED OUTCOME Evidence-Backed Confidence
Fig. iv.
Explore the Platform

§ V

Value by Lifecycle

Value by Lifecycle Continuous commercial foresight. From Phase I design to final pricing negotiations, Tekmeria embeds market reality into every stage of clinical development—ensuring your asset’s value compounds with every decision.

Drug development lifecycle atlas: six phases bound by three long-staple stage brackets, threaded by a Copper engagement spine that ascends in discrete shelves through the lifecycle. i. ii. iii. PRE-CLINICAL PHASE I PHASE II PHASE III REVIEW POST-MARKET Y−10 → Y−6 Y−6 → Y−4.5 Y−4.5 → Y−2.5 Y−2.5 → Y−0.5 Y−0.5 → Y 0 Y 0 → Y+5 IND Phase II read-out NDA FDA EMA +Label Y−10 Y−7 Y−4 Y−1 Y 0 Y+3 Y+5 Y+5 · 0.94

i.

Early-Stage Development

Pre-Clinical & Phase I

We align clinical strategy with commercial viability before the most expensive investments are made.

ii.

Clinical Development

Phase II & Phase III

Navigating high-stakes decisions where errors are irreversible. Determining the correct trials design.

iii.

Post-Market Authorization

Launch & Life Cycle

Strategies for label expansion and price defense to maximize total lifetime value.

See Value at Every Stage